Article
Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Clinical therapeutics - 1 Feb 2024
Vonk Steffie E M, Lub Rianne, Weersink Els J M, Beuers Ulrich, Mathôt Ron A A, Kemper E Marleen, Altenburg Josje
Abstract excerpt
PURPOSE: Cystic fibrosis (CF) is a monogenetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein and affecting multiple organs, including the lungs and liver. Almost 90% of people affected carry at least 1 Phe508del CFTR mutation. Medical treatment with the CFTR-modulating drug elexacaftor-tezacaftor-ivacaftor (ETI) has been proven to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.